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Summary During a clinical trial of duration of chemotherapy in small cell lung cancer (SCLC), 71 of 610
patients (11.6%) died in the first 3 weeks. Chemotherapy consisted of cyclophosphamide 1 gim-2 i.v. day 1,
etoposide 100mg t.d.s. orally days 1-3, vincristine 2mg i.v. day 1. The time of death was found to be non-
randomly distributed within the first chemotherapy cycle, with a peak incidence between days 7 and 12 after
chemotherapy. Patients were matched with controls who were the next cases entered into the study who did
not die in the first 3 weeks. Patients dying early were more likely to have clinical hepatomegaly (P<0.0001),
and ECOG score >1 (P<0.00001). As a group these patients also had a higher alkaline phosphatase
(P<0.0002), an elevated blood urea (P<0.00001) and a lower serum albumin (P<0.0001) than controls. It is
probable that infection contributes to the death of these already ill patients at a time when the blood count is
low. Early deaths have been noted in two other large trials using regimens including etoposide. Prophylactic
antibiotics or dosage modification may prevent the early death of these high risk patients.
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initial treatment was made on the basis of performance
status or biochemical tests of liver and renal function.
Patients (P) who died in the first 3 weeks were identified
and clinical and biochemical parameters, recorded at
presentation, were compared with a control group (C) who
consisted of the next patient entering the study who did not
die in the first 3 weeks. The clinical features examined were
performance status (PS) using the ECOG score; disease
extent; presence or absence of SVC obstruction; palpable
lymphadenopathy; palpable hepatomegaly; and bone scan
evidence of metastases. Of these parameters, PS and disease
extent were recorded on the computer data base as part of
the registration details. The other clinical data were collected
from the case notes. It is for this reason that the comparison
is made with a control group of equal size rather than with
the entire trial. For those parameters recorded on the trial
registration forms the data are given for both the control
group and the entire trial. Plasma urea, alkaline
ts in the randomised phosphatase, sodium and albumin were also compared since
these factors had previously been shown to have prognostic
significance in other studies (Souhami et al., 1985). In
analysing the values obtained from several different
hospitals, each of which adopts a different normal range and
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been made as a percentage of the upper limit of the normal
range for each laboratory, and the values of plasma albumin,
sodium and blood urea are expressed as a percentage of the
mean of the hospitals' normal range.
Statistical tests were x2 for the comparisons of clinical
features and the t test for the unpaired biochemical values.
Results
Discussion
It has long been recognised that patients who are in a poor
state of health are more susceptible to chemotherapy-induced
toxicity, but there have been few studies which have
attempted to analyse the predisposing factors. Such studies
might be useful not only to avoid toxicity by defining groups
at risk, but might also be helpful in pointing to possible
causes of alteration in the pharmacology of cytotoxic drugs
There were 610 patients in the trial and 71 deaths in the first
3 weeks. The characteristics of all patients in the trial, the
patients dying early and the controls are shown in Table I.
The patients dying early had similar median ages and age
ranges, and similar sex ratio as the controls and the entire
study group. There were more patients with extensive disease
in the group dying early than in the controls (P=0.05). The
day of death in the first chemotherapy cycle was analysed
and found to be non-randomly distributed (Figure 2). The
highest death rate was during the period 7-12 days after the
administration of chemotherapy, which coincides with the
expected nadir of the white blood count. Nadir counts were
not performed as a routine in this study, so no direct
comparison of blood counts in patients and controls can be
made. Apart from disease extent two other clinical factors
were strongly predictive for early death. These were poor PS
(P<0.00001, Figure 3), and palpable hepatomegaly (P vs.
C=61% vs 23%, P<0.0001). Palpable lymphadenopathy
was present in 28.9% of patients, abnormal bone scan in
50% and SVC obstruction in 11.5% with no difference
between patients and controls.
In patients dying early the mean percentage of upper limit
of alkaline phosphatase was 235.5% compared with 115.9%
in the controls (P<0.0002, Table II). The distribution of
values is shown in Figure 4. The mean serum albumin was
81.1% of the mean of the normal range in the patients and
90.0% in the controls (P<0.00005). The distribution of these
values is shown in Figure 5. The mean blood urea (Figure 6)
was 175.1% of the mean of the normal range in the patient
group compared with 107.3% in the controls
(P= <0.00001). The mean plasma sodium (Table II) was
slightly lower in the early death group than in controls.
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Figure 2 Day of death for patients dying during the 21 days
following the administration of the first chemotherapy cycle
which began on day 1.
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Table I Characteristics ofpatients dying early, in the control
group, and in all patients in the trial (*excluding the early
death group)
Early deaths Controls All patients*
No. 71 71 539
L/E 9/62 19/52 187/352
L/E (%) 13/87 27/73 35/65
M/F 44/27 44/27 373/166
M/F (%) 62/38 62/38 69/31
Age range 38-74 31-72 31-74
Median 64 62 62
20 -
10 -
* Early deaths
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Figure 3 Initial ECOG
early and controls.
performance status in patients dying
Table II Biochemical characteristics, and performance status, in patients dying early, in the control group
and in all patients (exluding the early death group)
P values
Early deaths Controls All patients EdvC EdvAll
No. 71 71 539
ECOG PS
% 0-1 35.7 83.3 77.8
% 2-4 64.3 16.7 22.2 <0.00001 <0.00001
Alkaline phosphatasea 235.5+246.1 115.9+84.2 130.2+ 129.0 <0.0002 <0.00001
Ureab 175.1+102.8 107.3+41.1 110.4+44.8 <0.00001 <0.00001
Albuminb 81.1+13.3 90.0+11.4 89.6+11.5 <0.00005 <0.00001
Sodiumb 95.7+4.0 97.3+3.8 96.9+4.2 <0.02 <0.02
aMean % of the upper limit of the hospital's normal range +1 s.d.; bMean % of the mean of the
hospital's normal range +1 s.d.
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Figure 4 Distribution of initial alkaline phosphatase values
(expressed as % of upper limit of normal value for the hospital
laboratory) in patients and controls.
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Figure 5 Distribution of values of initial plasma albumin
(expressed as % of mean value for the hospital laboratory) in
patients and controls.
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Figure 6 Distribution of values of initial blood urea (expressed
as % of mean value for the hospital laboratory) in patients and
controls.
in these patients. In the study of Hirsch et al. (1987) the
survival curve shows an inflection after the first few weeks
similar to that shown in the present study. A recent trial
from the UK Medical Research Council (1989) has shown a
similar phenomenon. Both of these studies used regimens
containing etoposide.
The data presented here show that chemotherapy-induced
toxicity is almost certainly playing a part in these early
deaths. The maximum death rate at the period
corresponding to the onset of neutropenia is unlikely to have
another explanation. The demonstration of the non-random
distribution of the time of death can only be made in very
large studies. These analyses have been repeated using the
data of the UK Medical Research Council trial (1989) and
the cycle-related mortality has been confirmed in that large
study. Our data showed only a slight increase in number of
deaths in the second and subsequent cycles, implying that
the high risk patients mostly succumbed during the first
cycle. It is worth noting that many of these very sick patients
are often considered by their family practitioner to have died
from cancer and that the contribution of chemotherapy to
toxicity might therefore be underestimated in conventional
reporting of toxicity.
Our data clearly show the hepatic metastasis is strongly
associated with an increased risk of early death. Clinical
hepatomegaly and abnormal liver enzyme tests were very
significantly more frequent in patients than in controls.
Abnormal liver function tests are known to be associated
with altered pharmacokinetics of intravenous etoposide. The
area under the plasma concentration curve is higher in
patients with a raised alkaline phosphatase or with reduced
plasma albumin (Pfluger et al., 1987; Arbuck et al., 1985).
The volume of distribution in steady state is inversely
correlated to the level of plasma albumin (Pfluger et al.,
1987). These results support the interpretation of the present
results as being in part due to increased susceptibility to the
toxicity of etoposide in patients with abnormal hepatic
function. The effect of abnormal liver function on the
absorption distribution and metabolism of oral etoposide is
not known, but oral administration is associated with
considerable variation in bioavailability (Arbuck et al., 1985)
which may make toxicity less predictable. The fi serum half
life of vincristine is prolonged in patients with abnormal liver
function (Van den Berg et al., 1982), but this drug is not
associated with a degree of myelosuppression which would
contribute greatly to infection. Cyclophosphamide is
converted to its active metabolite by the liver and abnormal
liver function prolongs the half life of the parent, non-
cytotoxic, compound (Juma, 1984).
The contribution of a raised blood urea to early death
might be explained by decreased clearance of etoposide from
the circulation in patients with impaired renal function as
shown by Sessa et al. (1985). The causes of the raised blood
urea in our patients are not known with certainty but it
seems possible that some of the iller patients had a pre-renal
cause such as salt and water depletion.
The analysis shows that the patients at risk with this
regimen can be identified and a strategy adopted to avoid
infection such as reduction of the dose in the first cycle.
Alternatively we recommend that, if these high risk patients
receive a full dose of chemotherapy containing etoposide on
the first cycle, a nadir blood count is obtained and
consideration given to prophylactic antibiotics in those
patients who are neutropenic after the first cycle. It is
probably prudent to obtain nadir blood counts in further
cycles and to adjust subsequent doses in severely neutropenic
patients. Further studies on the pharmacology of oral and
intravenous etoposide in these patients would be very helpful
in trying to elucidate the pharmacological reasons for the
toxicity.
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